196 related articles for article (PubMed ID: 30400799)
1. Status of programmed death-ligand 1 expression in sarcomas.
Park HK; Kim M; Sung M; Lee SE; Kim YJ; Choi YL
J Transl Med; 2018 Nov; 16(1):303. PubMed ID: 30400799
[TBL] [Abstract][Full Text] [Related]
2. PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Torabi A; Amaya CN; Wians FH; Bryan BA
Pathology; 2017 Aug; 49(5):506-513. PubMed ID: 28688724
[TBL] [Abstract][Full Text] [Related]
3. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic Sarcomas, Liposarcomas and Chondrosarcomas.
Zhang Y; Chen Y; Papakonstantinou A; Tsagkozis P; Linder-Stragliotto C; Haglund F
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204793
[TBL] [Abstract][Full Text] [Related]
5. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL
Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396
[TBL] [Abstract][Full Text] [Related]
6. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma - correlation with clinicopathological data and comparison of antibodies.
Kriegsmann M; Roessler S; Kriegsmann K; Renner M; Longuespée R; Albrecht T; Loeffler M; Singer S; Mehrabi A; Vogel MN; Pathil A; Köhler B; Springfeld C; Rupp C; Weiss KH; Goeppert B
BMC Cancer; 2019 Jan; 19(1):72. PubMed ID: 30646854
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of PD-L1 expression in matched recurrent and/or metastatic sarcoma samples and in a range of selected sarcomas subtypes.
Vargas AC; Maclean FM; Sioson L; Tran D; Bonar F; Mahar A; Cheah AL; Russell P; Grimison P; Richardson L; Gill AJ
PLoS One; 2020; 15(4):e0222551. PubMed ID: 32294103
[TBL] [Abstract][Full Text] [Related]
8. The clinical outcomes of undifferentiated pleomorphic sarcoma (UPS): A single-centre experience of two decades with the assessment of PD-L1 expressions.
Lee K; Song JS; Kim JE; Kim W; Song SY; Lee MH; Chung HW; Cho KJ; Lee JS; Ahn JH
Eur J Surg Oncol; 2020 Jul; 46(7):1287-1293. PubMed ID: 32127249
[TBL] [Abstract][Full Text] [Related]
9. The PD-L1/PD-1 axis expression on tumor-infiltrating immune cells and tumor cells in pediatric rhabdomyosarcoma.
Gabrych A; Pęksa R; Kunc M; Krawczyk M; Izycka-Swieszewska E; Biernat W; Bień E
Pathol Res Pract; 2019 Dec; 215(12):152700. PubMed ID: 31704149
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas.
Kelany M; Barth TF; Salem D; Shakweer MM
Pathol Oncol Res; 2021; 27():1609804. PubMed ID: 34276259
[No Abstract] [Full Text] [Related]
11. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
[TBL] [Abstract][Full Text] [Related]
12. Clinical and prognostic significance of PD-1 and PD-L1 expression in sarcomas.
Paydas S; Bagir EK; Deveci MA; Gonlusen G
Med Oncol; 2016 Aug; 33(8):93. PubMed ID: 27421997
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
14. Characterization of PD-1/PD-L1 immune checkpoint expression in soft tissue sarcomas.
Hashimoto K; Nishimura S; Ito T; Akagi M
Eur J Histochem; 2021 Jul; 65(3):. PubMed ID: 34218652
[TBL] [Abstract][Full Text] [Related]
15. RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer.
Zavalishina L; Tsimafeyeu I; Povilaitite P; Raskin G; Andreeva Y; Petrov A; Kharitonova E; Rumyantsev A; Pugach I; Frank G; Tjulandin S
Virchows Arch; 2018 Dec; 473(6):719-724. PubMed ID: 30209552
[TBL] [Abstract][Full Text] [Related]
16. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
[TBL] [Abstract][Full Text] [Related]
17. Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.
Keung EZ; Burgess M; Salazar R; Parra ER; Rodrigues-Canales J; Bolejack V; Van Tine BA; Schuetze SM; Attia S; Riedel RF; Hu J; Okuno SH; Priebat DA; Movva S; Davis LE; Reed DR; Reuben A; Roland CL; Reinke D; Lazar AJ; Wang WL; Wargo JA; Tawbi HA
Clin Cancer Res; 2020 Mar; 26(6):1258-1266. PubMed ID: 31900276
[TBL] [Abstract][Full Text] [Related]
18. [Consistency of PD-L1 immunohistochemical detection platforms in biopsy samples with advanced lung adenocarcinoma: a multicenter study].
Yuan P; Guo CY; Li Y; Jiang LL; Liu YP; Liu XY; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2018 Nov; 47(11):840-844. PubMed ID: 30423607
[No Abstract] [Full Text] [Related]
19. Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas.
Asanuma K; Nakamura T; Hayashi A; Okamoto T; Iino T; Asanuma Y; Hagi T; Kita K; Nakamura K; Sudo A
Sci Rep; 2020 Jun; 10(1):9077. PubMed ID: 32493964
[TBL] [Abstract][Full Text] [Related]
20. Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma.
Tessier-Cloutier B; Kalloger SE; Al-Kandari M; Milne K; Gao D; Nelson BH; Renouf DJ; Sheffield BS; Schaeffer DF
BMC Cancer; 2017 Sep; 17(1):618. PubMed ID: 28870260
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]